In contrast to many candidates being clinically tested as potential NASH therapeutics, FGF21 not only exerts direct effects on the liver to improve its metabolic state, but also acts on whole body metabolism to lighten the metabolic load on the liver. The gene discussed is FGF21; the disease is metabolic dysfunction-associated steatohepatitis.